A double-blind, randomized, multicenter, placebo-controlled, parallel-group study to evaluate the efficacy and safety of fingolimod 0.5 mg administered orally once daily versus placebo in patients with CIPD
Study for treating patients with neuropathy using study drug fingolimod
Sponsor: Novartis Pharmaceuticals
Enrolling: Male and Female Patients
Study Length: 2 Years
Clinic Visits: 18
IRB Number: AAAK6804
U.S. Govt. ID: NCT01625182
Contact: Jacqueline Scoon: 212 305 6035 / js4462@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the efficacy and safety of study drug, fingolimod taken daily compared with a placebo (does not contain active medication) on delaying disability progression in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study will consist of 3 periods: a Screening Period (lasting for up to 45 days), a Treatment Period, and a Follow-up Period after discontinuation of study drug treatment.
This study is closed
Thomas Brannagan, MD
Do You Qualify?
Do you have a confirmed diagnosis of CIDP? Yes No
Have you been diagnosed with diabetes mellitus? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Jacqueline Scoon
212 305 6035